Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Bella Hadid goes braless in a thigh
VOX POPULI: Professionalism will be the key to successful ride
Six dead after knife attack outside kindergarten in Chinese city
Small businesses account for 71% of jobs created up to September
Jon Wysocki dead at 53: Staind drummer passes away
Video captures scary moments as speedway car crashes over safety fence
Shocking video of a Rottweiler mauling 2
Waikato schoolchildren pitch into major kiwi relocation project
Red Lobster seeks bankruptcy protection after closing some restaurants
Earth's inner core made up of superionic matter, Chinese study says
Russian theater director and playwright go on trial over a play authorities say justifies terrorism
US sends two warships through Taiwan Strait in first transit since Pelosi trip